InscoBio "Oncotag, 94.5% Accuracy in Diagnosing Bile Duct Cancer... Published in Leading Endoscopy Journal"

[Asia Economy Reporter Hyunseok Yoo] Insukobi announced on the 12th that the results of a domestic multi-center clinical study on bile duct cancer diagnosis using the MARS1 antibody of its subsidiary Oncotag Diagnostic (hereinafter Oncotag) were published in ‘Gastrointestinal Endoscopy,’ the official journal of the American Society for Gastrointestinal Endoscopy, a leading journal in the field of endoscopy.

Through the study, Oncotag confirmed that applying the antibody MARS1, which it independently developed and produced, as a staining marker for bile duct cell staining diagnosis showed higher diagnostic accuracy compared to the existing staining method (Pap Stain). The sensitivity was 93.6%, about 20% higher than the existing method’s sensitivity of 73.2%, and the accuracy was also 94.5%, 15% higher than the existing method’s 80.7%.

These research results are significant for bile duct cancer diagnosis, where early detection is crucial due to the nature of the cancer. They highlight the excellence of the antibody produced by Oncotag and the potential to develop bile duct cancer diagnostic kits utilizing it, attracting attention. Based on this, Oncotag is expected to gain momentum in developing bile duct cancer diagnostic kit products.

This study involved six leading university hospitals in Korea, centered on the gastroenterology research team at Gangnam Severance Hospital, including Gachon University Gil Medical Center, Inha University Inha University Hospital, CHA University Bundang CHA Hospital, Pusan National University Hospital, and Soonchunhyang University Cheonan Soonchunhyang Hospital.

Choi Dongjae, CEO of Oncotag, stated, “This research result is a meaningful achievement demonstrating the excellence of the MARS1 antibody developed by Oncotag as a diagnostic marker for bile duct cancer. Based on the research results, we will focus on developing products with higher accuracy and user-friendliness, while also expanding the indications of the products to lung cancer, thyroid cancer, and others.”

This content was produced with the assistance of AI translation services.